Latest Post

December 23, 2020

Container Closure Integrity Evaluation for Cell and Gene Therapies

With the growth of gene and cell therapies, there is an increased need to characterize container closure systems (CCS) at the low temperatures experienced during their lifecycles: ultra-low (-80°C) for genes and cryogenic (-180°C) for cells. West’s Integrated Solutions platform includes the state-of-the-art container closure integrity (CCI) capabilities needed for these therapies.
Olga Laskina

Olga Laskina, PhD.

Sr. Technical Account Specialist, TCS NA

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • Previous Posts
    Patient with nurse getting treatment

    September 16, 2020

    Why a Diagnosis of Leukemia Means a Possibly Complicated Journey Ahead

    Victoria Morgan

    Victoria Morgan

    Director, Segment Marketing, Global Biologics

    Introducing Integrated Solutions

    May 15, 2020

    Speed to Market with a Platform Approach

    Fran DeGrazio

    Fran DeGrazio

    Chief Scientific Officer, Scientific Affairs

    SmartDose Platform

    June 27, 2019

    Industry Trends in Biologic Formulations

    Victoria Morgan

    Victoria Morgan

    Director, Segment Marketing, Global Biologics

    SmartDose In-Use

    May 07, 2019

    The Impact Poor Formulations Have on Drug Development Programs

    Victoria Morgan

    Victoria Morgan

    Director, Segment Marketing, Global Biologics

    SmartDose Platform

    April 26, 2019

    Overcoming Challenges Associated with Biologic Drug Formulation and Development

    Victoria Morgan

    Victoria Morgan

    Director, Segment Marketing, Global Biologics